SEC filings and other documents

Clinical progress and improved financials position the company for key data milestones in 2026-2027.

PGN-EDODM1 delivers robust splicing correction and favorable safety in DM1 trials.

Q1 2026 net loss narrowed, FREEDOM2 trial progressed, and cash runway extends into 2H 2027.

PGN-EDODM1 delivers strong splicing correction and safety in DM1, with pivotal data ahead.

PGN-EDODM1 shows strong efficacy and safety in DM1, with pivotal data expected by 2027.

FREEDOM2's 5 mg/kg cohort showed promising safety and efficacy, supporting dose escalation.

Record splicing improvements and robust safety data drive global DM1 trial progress.

PGN-EDODM1 shows best-in-class splicing correction and strong safety in DM1 trials.

Advancing DM1 clinical program with strong cash position and key data readouts expected in 2026.

DM1 trials achieved record splicing gains and strong safety, with pivotal data due Q1 next year.

Record splicing correction in DM1 and strong cash position set stage for key 2026 milestones.

PGN-EDODM1 achieved record splicing correction and strong safety in DM1, with pivotal data ahead.

DM1 program shows best-in-class splicing correction and safety, with pivotal data due next year.

15 mg/kg FREEDOM trial cohort completed; Q2 net loss narrows, cash runway into Q2 2026.

PGN-EDODM1 demonstrates strong safety and efficacy signals in DM1, with pivotal data expected in 2025–2026.

Positive DM1 data and upcoming DMD milestones highlight PepGen's catalyst-rich 2025.

Upcoming clinical milestones for DM1 and DMD programs signal strong progress and value creation.

DM1 and DMD programs show strong efficacy and safety, with key data readouts expected this year.

DM1 and DMD programs show strong efficacy and safety, with pivotal data expected soon.

PGN-EDODM1 delivers best-in-class splicing correction and strong safety in DM1 trials.

PepGen posted a $90M net loss in 2024, with strong cash reserves but ongoing regulatory and funding risks.